Skip to main content
Premium Trial:

Request an Annual Quote

Where Are They Now?: Sep 1, 2003

Premium

Last year’s issue of Genome Technology took you inside the new Arizona cancer genomics initiative called the International Genomics Consortium. Since then, the IGC has continued to gain momentum. In March it named Michael Berens CEO, and Robert Penny as chief medical officer. And by June, the consortium heralded the groundbreaking of its home-to-be in downtown Phoenix. The $46 million facility, also occupied by the Translational Genomics Research Institute, is expected to be open in November of next year.

The September ’02 issue also looked at the upcoming merger of Pfizer and Pharmacia. That deal closed in April, and the acquisition helped Pfizer’s Discovery Technology Center (see p. 19).

GT also checked in on compensation packages for genomics execs, listing some of the stranger perks used to lure people to different companies. In the year since, the magazine launched the industry’s first genomics salary survey, finding that the median salary range is currently $75,000 to $99,000.

Finally, IT Guy Nat Goodman gave you his second back-to-school feature, a roundup of online courses. This year, Nat pursues the same theme and looks at the lousy bioinformatics job market and what bioinformaticists need to do to keep themselves relevant (see p. 36).

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.